Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT04721132
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Resectable Hepatocellular Carcinoma
  • Stage I Hepatocellular Carcinoma AJCC v8
  • Stage IA Hepatocellular Carcinoma AJCC v8
  • Stage IB Hepatocellular Carcinoma AJCC v8
  • Stage II Hepatocellular Carcinoma AJCC v8

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — BIOLOGICAL
    Given IV
  • Bevacizumab — BIOLOGICAL
    Given IV
  • Therapeutic Conventional Surgery — PROCEDURE
    Undergo surgery

Study Details

This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving the combination of atezolizumab and bevacizumab may help to prevent liver cancer from returning after surgery.

Key Dates

Start date
Feb 10, 2021
Status verified
Mar 2026
Primary completion
May 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
16 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (atezolizumab, bevacizumab)
    Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery during week 12.

Primary Outcome Measure

Pathologic complete response (pCR) rate [ Time Frame: Up to 2 years post-treatment ]

Locations (2)

FacilityCityStateZIPSite coordinators
Houston Methodist HospitalHoustonTexas77030-
M D Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
Houston Methodist Hospital· Houston, TXM D Anderson Cancer Center· Houston, TX

Related Studies